

This document is intended to provide health care providers with approaches for individuals who have received COVID-19 vaccination outside of Canada. The WHO list of EUA qualified COVID-19 vaccines will be updated over time as additional COVID-19 vaccines receive emergency use listing, and as such, this document will be updated accordingly. More information on COVID-19 vaccines listed for emergency use can be found on the [WHO website](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports), under the tab “Status of COVID-19 vaccines within WHO EUL/PQ evaluation process.”

Manufacturer	Name of Vaccine	Type of vaccine	WHO EUA qualified	Approved Schedule for primary series <sup>1, 2</sup>	Second dose options for completion of series in BC <sup>3</sup>
Pfizer-BioNTech	BNT162b2 / COMIRNATY / Tozinameran (INN)	mRNA	✓	Two doses, 21-28 days apart	- Moderna - Pfizer-BioNTech
Moderna	mRNA-1273	mRNA	✓	Two doses, 28 days apart	- Moderna - Pfizer-BioNTech
AstraZeneca	AZD1222 Vaxzevria	Adenovirus (CHAdOx1) vector	✓	Two doses, 4-12 weeks apart	- Moderna - Pfizer-BioNTech
Serum Institute of India	COVISHIELD	Adenovirus (CHAdOx1) vector	✓	Two doses, 4-12 weeks apart	- Moderna - Pfizer-BioNTech
Janssen (Johnson & Johnson)	Ad26.COV2.5	Adenovirus type 26 vector	✓	One dose	N/A - one dose series
SinoPharm / Beijing Institute of Biological Products (BIBP) <sup>4</sup>	Covilo / BBIBP-CorV	Whole inactivated Coronavirus	✓	Two doses, 21-28 days apart Note: Age extension to 3-17 (Apr.17, 2023)	- Moderna - Pfizer-BioNTech
Sinovac	CoronaVac	Whole inactivated Coronavirus	✓	Two doses, 14-28 days apart Note: Age extension to 3-17 (Nov. 2, 2022)	- Moderna - Pfizer-BioNTech
Bharat Biotech, India	COVAXIN	Whole inactivated Coronavirus	✓	Two doses, 28 days apart	- Moderna - Pfizer-BioNTech
Novavax	NVX-CoV2373 / Nuvaxovid	Protein subunit	✓	Two doses, 21-28 days apart	- Moderna - Pfizer-BioNTech - Novavax
Serum Institute of India	NVX-CoV2373 / Covovax	Protein subunit	✓	Two doses, 21-28 days apart Note: Age extension to 12-17 (Nov. 17, 2022)	- Moderna - Pfizer-BioNTech
CanSinoBio	Ad5-nCoV	Adenovirus Type 5 vector	✓	One dose	N/A - one dose series
Russian Direct Investment Fund	Sputnik V	Human adenovirus vector	pending		

Manufacturer	Name of Vaccine	Type of vaccine	WHO EUA qualified	Approved Schedule for primary series <sup>1, 2</sup>	Second dose options for completion of series in BC <sup>3</sup>
Sanofi	CoV2 preS dTM-AS03 vaccine	Recombinant, adjuvanted	pending		
Clover Biopharmaceuticals	SCB-2019	Recombinant protein subunit	pending		
Zhifei Longcom (China)	Recombinant Novel Coronavirus Vaccine	Recombinant protein subunit	pending		
Shifa Pharmed-Barkat	CovIran <sup>®</sup> vaccine	Whole inactivated Coronavirus	pending		
CIGB	Abdala	Protein subunit	pending		
SK Bioscience	Nuvaxovid prefilled syringe	Protein subunit	pending		
Biological E	Corbevax	Protein subunit	pending		
SK Bioscience	GBP510	Recombinant protein subunit	pending		

<sup>1</sup> Individuals who have received a complete series with a vaccine that is WHO EUA qualified are considered fully vaccinated within the primary series. However, one additional dose of a COVID-19 mRNA vaccine should be provided for individuals upon request if they have been vaccinated with 2 doses of a WHO-approved vaccine series that is not authorized in Canada. The minimum interval between the preceding dose and the additional dose is 4 weeks. If they have already received three or more doses of a WHO-approved/non-Health Canada approved COVID-19 vaccine, they do not need an additional dose unless they are due for a booster dose (i.e., a bivalent COVID-19 mRNA vaccine). If an individual < 18 years of age receives a WHO-approved vaccine that is not authorized in Canada for one or more doses, this can be considered valid.

<sup>2</sup> Individuals who have received a series with a vaccine that is not WHO EUA qualified should be offered a full COVID-19 vaccine series using a vaccine available in BC. There is no minimum interval required when restarting the series following receipt of a non-WHO approved vaccine.

<sup>3</sup> A COVID-19 mRNA vaccine is preferred. Novavax COVID-19 vaccine may be offered to individuals for whom COVID-19 mRNA vaccines are contraindicated or have been refused. Novavax COVID-19 vaccine is interchangeable with mRNA and viral vector COVID-19 vaccines within the primary series and/or booster dose. An 8 week interval between doses is recommended. A minimum interval of 4 weeks is acceptable, if required.

<sup>4</sup> This includes BIBP products from Chengdu Institute of Biological Products (CIBP); Lanzhou Institute of Biological Products (LIBP) and Changchun Institute of Biological Products (CCIBP).